Urogen Pharma (NASDAQ:URGN) Receives $33.00 Consensus Target Price from Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $33.00.

A number of research firms recently weighed in on URGN. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Urogen Pharma in a research report on Monday, October 27th. Wall Street Zen raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Friday, January 23rd.

Insider Activity

In other news, insider Mark Schoenberg sold 7,373 shares of Urogen Pharma stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the completion of the transaction, the insider owned 144,985 shares in the company, valued at $2,854,754.65. This trade represents a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of URGN. AQR Capital Management LLC raised its holdings in Urogen Pharma by 347.5% during the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after acquiring an additional 88,577 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after purchasing an additional 1,653 shares during the period. Jane Street Group LLC lifted its holdings in Urogen Pharma by 94.3% during the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after purchasing an additional 24,839 shares in the last quarter. Truist Financial Corp bought a new position in Urogen Pharma in the 2nd quarter worth about $423,000. Finally, Bender Robert & Associates bought a new position in Urogen Pharma in the 2nd quarter worth about $475,000. 91.29% of the stock is owned by institutional investors.

Urogen Pharma Price Performance

NASDAQ URGN opened at $21.35 on Wednesday. The stock has a market capitalization of $999.39 million, a P/E ratio of -6.17 and a beta of 1.33. The business has a 50 day simple moving average of $21.96 and a 200 day simple moving average of $20.68. Urogen Pharma has a one year low of $3.42 and a one year high of $30.00.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.03. The firm had revenue of $27.48 million during the quarter, compared to the consensus estimate of $34.09 million. Equities analysts expect that Urogen Pharma will post -3.12 earnings per share for the current year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.